STANDARD BIOTOOLS INC. LAB
At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M | $138.1M | $117.2M | $113.0M | $101.9M | $104.4M |
| Cost of revenue | $42.8M | $46.1M | $55.9M | $60.9M | — | — | $53.0M | $51.3M | $50.0M | $46.0M |
| Gross profit | $42.5M | $44.9M | $50.5M | $37.1M | — | — | $64.3M | $61.6M | $52.0M | $58.4M |
| R&D | $26.0M | $28.8M | $25.9M | $37.4M | $37.9M | $36.5M | $31.6M | $30.0M | $30.8M | $38.4M |
| SG&A | $109.9M | $103.1M | $87.5M | $102.3M | $98.9M | $97.9M | $84.5M | $79.8M | $79.5M | $93.2M |
| Total operating expenses | $152.8M | $172.4M | $127.0M | $153.3M | $198.0M | $189.2M | $169.1M | $161.1M | $110.3M | $131.6M |
| Operating income | -$110.2M | -$127.5M | -$76.6M | -$116.2M | -$67.5M | -$51.0M | -$51.8M | -$48.2M | -$58.4M | -$73.2M |
| Interest expense | — | — | $4.6M | $4.3M | $3.8M | $3.6M | $4.3M | $13.9M | $5.8M | $5.8M |
| Pre-tax income | -$96.7M | -$90.4M | -$74.2M | -$192.9M | -$63.7M | -$54.1M | -$66.7M | -$61.4M | -$63.8M | -$80.2M |
| Income tax | $37.9M | $542.0K | $452.0K | $2.8M | $4.4M | $1.1M | $1.9M | $2.4M | $3.3M | $4.2M |
| Net income | -$74.9M | -$138.9M | -$74.7M | -$190.1M | -$59.2M | -$53.0M | -$64.8M | -$59.0M | -$60.5M | -$76.0M |
| EPS, basic | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | — | — | — |
| EPS, diluted | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 |
| Shares, diluted (wtd. avg.) | $381.6M | $353.2M | $79.2M | $78.3M | $75.8M | $72.0M | $66.8M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $120.9M | $166.7M | $52.5M | $82.3M | $29.5M | $69.5M | $23.7M | $95.4M | $58.1M | $35.0M |
| Short-term investments | $66.7M | $126.1M | $63.2M | $84.5M | $0 | $0 | $37.0M | $0 | $5.1M | $24.4M |
| Receivables | $13.4M | $14.7M | $19.7M | $17.3M | $18.3M | $25.4M | $19.0M | $16.7M | $15.0M | $14.6M |
| Inventory | $20.0M | $20.7M | $20.5M | $21.5M | $20.8M | $19.7M | $13.9M | $13.0M | $15.1M | $20.1M |
| Total current assets | $454.3M | $375.9M | $158.2M | $208.8M | $72.1M | $117.7M | $96.1M | $127.1M | $94.8M | $96.7M |
| Property, plant and equipment | $19.3M | $22.8M | $24.2M | $25.7M | $28.0M | $17.5M | $8.1M | $8.8M | $12.3M | $16.5M |
| Goodwill | — | $111.3M | $106.3M | $106.3M | $106.4M | $106.6M | $104.1M | $104.1M | $104.1M | $104.1M |
| Other intangibles | — | $29.0M | $1.4M | $12.6M | $27.9M | $40.2M | $46.2M | $57.4M | $68.6M | $79.8M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M | $324.8M | $264.8M | $303.6M | $287.4M | $306.4M |
| Accounts payable | $5.4M | $5.0M | $9.2M | $7.9M | $10.6M | $9.2M | $5.2M | $4.0M | $4.2M | $4.0M |
| Total current liabilities | $108.3M | $65.9M | $109.3M | $43.4M | $49.6M | $54.2M | $32.8M | $37.6M | $33.5M | $29.5M |
| Long-term debt | — | $299.0K | $63.5M | $64.9M | — | — | — | — | — | — |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M | $180.6M | $185.7M | $111.2M | $231.5M | $256.4M | $253.2M |
| Retained earnings | -$1.26B | -$1.19B | -$1.00B | -$926.1M | -$736.0M | -$676.8M | -$623.6M | -$558.9M | -$500.2M | -$439.5M |
| Total equity | $424.3M | $471.7M | -$148.1M | -$81.5M | $94.6M | $139.1M | $153.6M | $72.1M | $30.9M | $53.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$74.3M | -$143.5M | -$43.3M | -$89.4M | -$44.1M | -$15.4M | -$35.2M | -$25.2M | -$24.1M | -$39.1M |
| Depreciation and amortisation | $9.3M | $12.5M | $4.0M | $3.5M | $3.2M | $4.0M | $4.6M | $5.4M | $7.4M | $6.7M |
| Stock-based compensation | $29.6M | $31.7M | $13.1M | $14.9M | $16.1M | $14.5M | $11.4M | $11.0M | $9.1M | $13.9M |
| Capital expenditure | $8.3M | $8.4M | $2.8M | $3.8M | $13.3M | $12.7M | $2.5M | $372.0K | $1.6M | $5.1M |
| Investing cash flow | $27.4M | $363.2M | $20.2M | -$88.1M | -$11.9M | $40.0M | -$39.3M | $4.7M | $17.7M | $45.1M |
| Financing cash flow | $570.0K | -$102.6M | -$6.8M | $230.8M | $16.0M | $20.9M | $2.8M | $57.7M | $29.0M | $116.0K |
| Buybacks | $0 | $40.5M | $5.4M | $563.0K | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017100.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |